{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:05Z","timestamp":1787003405347,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although efficacy of combined histone deacetylase (HDAC) inhibitors and conventional photon radiotherapy is being tested in clinical trials, their combined effect with proton beam radiotherapy has yet to be determined. Here, we compared combined effect of valproic acid (VPA), a class I and II HDAC inhibitor and antiepileptic drug with proton and photon irradiation in hepatocellular carcinoma (HCC) cells\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . We found that VPA sensitized more Hep3B cells to proton than to photon irradiation. VPA prolonged proton-induced DNA damage and augmented proton-induced apoptosis. In addition, VPA further increased proton-induced production of intracellular reactive oxygen species and suppressed expression of nuclear factor erythroid-2-related factor 2 (NRF2), a key transcription factor regulating antioxidant response. Downregulation of NRF2 by siRNA transfection increased proton-induced apoptotic cell death, supporting NRF2 as a target of VPA in radiosensitization. In Hep3B tumor xenograft models, VPA significantly enhanced proton-induced tumor growth delay with increased apoptosis and decreased NRF2 expression\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Collectively, our study highlights a proton radiosensitizing effect of VPA in HCC cells. As NRF2 is an emerging prognostic marker contributing to radioresistance in HCC, targeting NRF2 pathway may impact clinical outcome of proton beam radiotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-15165-3","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T08:07:39Z","timestamp":1509610059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation"],"prefix":"10.1038","volume":"7","author":[{"given":"Jeong Il","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arang","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Haeng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Yeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"15165_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","volume":"1","author":"JM Wagner","year":"2010","unstructured":"Wagner, J. M., Hackanson, B., Lubbert, M. & Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1, 117\u2013136, https:\/\/doi.org\/10.1007\/s13148-010-0012-4 (2010).","journal-title":"Clin Epigenetics"},{"key":"15165_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/excr.2000.5080","volume":"262","author":"SG Gray","year":"2001","unstructured":"Gray, S. G. & Ekstrom, T. J. The human histone deacetylase family. Exp Cell Res 262, 75\u201383, https:\/\/doi.org\/10.1006\/excr.2000.5080 (2001).","journal-title":"Exp Cell Res"},{"key":"15165_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/47412","volume":"403","author":"BD Strahl","year":"2000","unstructured":"Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41\u201345, https:\/\/doi.org\/10.1038\/47412 (2000).","journal-title":"Nature"},{"key":"15165_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/bjc.2013.21","volume":"108","author":"B Groselj","year":"2013","unstructured":"Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M. & Kiltie, A. E. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108, 748\u2013754, https:\/\/doi.org\/10.1038\/bjc.2013.21 (2013).","journal-title":"Br J Cancer"},{"key":"15165_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124, 30\u201339, https:\/\/doi.org\/10.1172\/jci69738 (2014).","journal-title":"J Clin Invest"},{"key":"15165_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2010","unstructured":"Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in cancer. Carcinogenesis 31, 27\u201336, https:\/\/doi.org\/10.1093\/carcin\/bgp220 (2010).","journal-title":"Carcinogenesis"},{"key":"15165_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","volume":"363","author":"MA Glozak","year":"2005","unstructured":"Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15\u201323, https:\/\/doi.org\/10.1016\/j.gene.2005.09.010 (2005).","journal-title":"Gene"},{"key":"15165_CR8","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","volume":"121","author":"F Santoro","year":"2013","unstructured":"Santoro, F. et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121, 3459\u20133468, https:\/\/doi.org\/10.1182\/blood-2012-10-461988 (2013).","journal-title":"Blood"},{"key":"15165_CR9","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281, 13548\u201313558, https:\/\/doi.org\/10.1074\/jbc.M510023200 (2006).","journal-title":"J Biol Chem"},{"key":"15165_CR10","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane, A. A. & Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27, 5459\u20135468, https:\/\/doi.org\/10.1200\/jco.2009.22.1291 (2009).","journal-title":"J Clin Oncol"},{"key":"15165_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3857\/roj.2015.33.4.337","volume":"33","author":"K Chung","year":"2015","unstructured":"Chung, K. et al. The first private-hospital based proton therapy center in Korea; status of the Proton Therapy Center at Samsung Medical Center. Radiat Oncol J 33, 337\u2013343, https:\/\/doi.org\/10.3857\/roj.2015.33.4.337 (2015).","journal-title":"Radiat Oncol J"},{"key":"15165_CR12","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S1470-2045(14)70412-7","volume":"16","author":"T Kamada","year":"2015","unstructured":"Kamada, T. et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 16, e93\u2013e100, https:\/\/doi.org\/10.1016\/s1470-2045(14)70412-7 (2015).","journal-title":"Lancet Oncol"},{"key":"15165_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3857\/roj.2016.01753","volume":"34","author":"JK Kang","year":"2016","unstructured":"Kang, J. K. et al. The clinical utilization of radiation therapy in Korea between 2009 and 2013. Radiat Oncol J 34, 88\u201395, https:\/\/doi.org\/10.3857\/roj.2016.01753 (2016).","journal-title":"Radiat Oncol J"},{"key":"15165_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","volume":"78","author":"C Blattmann","year":"2010","unstructured":"Blattmann, C. et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78, 237\u2013245, https:\/\/doi.org\/10.1016\/j.ijrobp.2010.03.010 (2010).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/cbr.2009.0629","volume":"24","author":"X Chen","year":"2009","unstructured":"Chen, X., Wong, P., Radany, E. & Wong, J. Y. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24, 689\u2013699, https:\/\/doi.org\/10.1089\/cbr.2009.0629 (2009).","journal-title":"Cancer Biother Radiopharm"},{"key":"15165_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","volume":"62","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan, P., Vallabhaneni, G., Armstrong, E., Huang, S. M. & Harari, P. M. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62, 223\u2013229, https:\/\/doi.org\/10.1016\/j.ijrobp.2004.12.088 (2005).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR17","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","volume":"5","author":"A Munshi","year":"2006","unstructured":"Munshi, A. et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5, 1967\u20131974, https:\/\/doi.org\/10.1158\/1535-7163.mct-06-0022 (2006).","journal-title":"Mol Cancer Ther"},{"key":"15165_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","volume":"11","author":"AH Ree","year":"2010","unstructured":"Ree, A. H. et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11, 459\u2013464, https:\/\/doi.org\/10.1016\/S1470-2045(10)70058-9 (2010).","journal-title":"Lancet Oncol"},{"key":"15165_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","volume":"86","author":"CA Barker","year":"2013","unstructured":"Barker, C. A., Bishop, A. J., Chang, M., Beal, K. & Chan, T. A. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86, 504\u2013509, https:\/\/doi.org\/10.1016\/j.ijrobp.2013.02.012 (2013).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze, A. V. et al. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys 92, 986\u2013992, https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.038 (2015).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR21","doi-asserted-by":"publisher","first-page":"R419","DOI":"10.1088\/0031-9155\/59\/22\/R419","volume":"59","author":"H Paganetti","year":"2014","unstructured":"Paganetti, H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol 59, R419\u2013472, https:\/\/doi.org\/10.1088\/0031-9155\/59\/22\/r419 (2014).","journal-title":"Phys Med Biol"},{"key":"15165_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijrobp.2010.07.020","volume":"79","author":"MA Dagrosa","year":"2011","unstructured":"Dagrosa, M. A. et al. First evaluation of the biologic effectiveness factors of boron neutron capture therapy (BNCT) in a human colon carcinoma cell line. Int J Radiat Oncol Biol Phys 79, 262\u2013268, https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.020 (2011).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-016-2054-8","volume":"127","author":"N Redjal","year":"2016","unstructured":"Redjal, N. et al. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide. J Neurooncol 127, 505\u2013514, https:\/\/doi.org\/10.1007\/s11060-016-2054-8 (2016).","journal-title":"J Neurooncol"},{"key":"15165_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3892\/ol.2013.1666","volume":"7","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. et al. Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett 7, 203\u2013208, https:\/\/doi.org\/10.3892\/ol.2013.1666 (2014).","journal-title":"Oncol Lett"},{"key":"15165_CR25","doi-asserted-by":"publisher","first-page":"35004","DOI":"10.18632\/oncotarget.5253","volume":"6","author":"D Thotala","year":"2015","unstructured":"Thotala, D. et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget 6, 35004\u201335022, https:\/\/doi.org\/10.18632\/oncotarget.5253 (2015).","journal-title":"Oncotarget"},{"key":"15165_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3892\/or.2015.4089","volume":"34","author":"N Makita","year":"2015","unstructured":"Makita, N. et al. Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. Oncol Rep 34, 1185\u20131192, https:\/\/doi.org\/10.3892\/or.2015.4089 (2015).","journal-title":"Oncol Rep"},{"key":"15165_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4143\/crt.2014.026","volume":"47","author":"EK Chie","year":"2015","unstructured":"Chie, E. K. et al. In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation. Cancer Res Treat 47, 527\u2013533, https:\/\/doi.org\/10.4143\/crt.2014.026 (2015).","journal-title":"Cancer Res Treat"},{"key":"15165_CR28","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.18632\/oncotarget.3692","volume":"6","author":"HY Chiou","year":"2015","unstructured":"Chiou, H. Y. et al. Valproic acid promotes radiosensitization in meningioma stem-like cells. Oncotarget 6, 9959\u20139969, https:\/\/doi.org\/10.18632\/oncotarget.3692 (2015).","journal-title":"Oncotarget"},{"key":"15165_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ijrobp.2014.03.034","volume":"89","author":"TS Hong","year":"2014","unstructured":"Hong, T. S. et al. A phase 1\/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys 89, 830\u2013838, https:\/\/doi.org\/10.1016\/j.ijrobp.2014.03.034 (2014).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR30","first-page":"1757","volume":"35","author":"H Ishikawa","year":"2015","unstructured":"Ishikawa, H. et al. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. Anticancer Res 35, 1757\u20131762 (2015).","journal-title":"Anticancer Res"},{"key":"15165_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jrr\/rru034","volume":"55","author":"Y Oshiro","year":"2014","unstructured":"Oshiro, Y. et al. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res 55, 959\u2013965, https:\/\/doi.org\/10.1093\/jrr\/rru034 (2014).","journal-title":"J Radiat Res"},{"key":"15165_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.radonc.2015.10.009","volume":"117","author":"JP Reddy","year":"2015","unstructured":"Reddy, J. P. et al. Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiother Oncol 117, 308\u2013314, https:\/\/doi.org\/10.1016\/j.radonc.2015.10.009 (2015).","journal-title":"Radiother Oncol"},{"key":"15165_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.radonc.2015.08.014","volume":"116","author":"AO Fontana","year":"2015","unstructured":"Fontana, A. O. et al. Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation. Radiother Oncol 116, 374\u2013380, https:\/\/doi.org\/10.1016\/j.radonc.2015.08.014 (2015).","journal-title":"Radiother Oncol"},{"key":"15165_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ijrobp.2014.12.046","volume":"91","author":"Q Liu","year":"2015","unstructured":"Liu, Q. et al. Lung cancer cell line screen links fanconi anemia\/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys 91, 1081\u20131089, https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.046 (2015).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijrobp.2013.09.041","volume":"88","author":"N Grosse","year":"2014","unstructured":"Grosse, N. et al. Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation. Int J Radiat Oncol Biol Phys 88, 175\u2013181, https:\/\/doi.org\/10.1016\/j.ijrobp.2013.09.041 (2014).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15165_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10495-005-3346-1","volume":"11","author":"C Di Pietro","year":"2006","unstructured":"Di Pietro, C. et al. Cellular and molecular effects of protons: apoptosis induction and potential implications for cancer therapy. Apoptosis 11, 57\u201366, https:\/\/doi.org\/10.1007\/s10495-005-3346-1 (2006).","journal-title":"Apoptosis"},{"key":"15165_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep13961","volume":"5","author":"R Alan Mitteer","year":"2015","unstructured":"Alan Mitteer, R. et al. Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen species. Sci Rep 5, 13961, https:\/\/doi.org\/10.1038\/srep13961 (2015).","journal-title":"Sci Rep"},{"key":"15165_CR38","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/0008-5472.CAN-06-0814","volume":"66","author":"Y Kawai","year":"2006","unstructured":"Kawai, Y. & Arinze, I. J. Valproic acid-induced gene expression through production of reactive oxygen species. Cancer Res 66, 6563\u20136569, https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0814 (2006).","journal-title":"Cancer Res"},{"key":"15165_CR39","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1124\/mol.105.017855","volume":"69","author":"EN Defoort","year":"2006","unstructured":"Defoort, E. N., Kim, P. M. & Winn, L. M. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 69, 1304\u20131310, https:\/\/doi.org\/10.1124\/mol.105.017855 (2006).","journal-title":"Mol Pharmacol"},{"key":"15165_CR40","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1073\/pnas.191208598","volume":"98","author":"AA Ruefli","year":"2001","unstructured":"Ruefli, A. A. et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98, 10833\u201310838, https:\/\/doi.org\/10.1073\/pnas.191208598 (2001).","journal-title":"Proc Natl Acad Sci USA"},{"key":"15165_CR41","first-page":"3637","volume":"63","author":"RR Rosato","year":"2003","unstructured":"Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1. Cancer Res 63, 3637\u20133645 (2003).","journal-title":"Cancer Res"},{"key":"15165_CR42","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-04-2440","volume":"65","author":"M Rahmani","year":"2005","unstructured":"Rahmani, M. et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1\/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65, 2422\u20132432, https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2440 (2005).","journal-title":"Cancer Res"},{"key":"15165_CR43","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood-2009-11-256354","volume":"116","author":"Y Hu","year":"2010","unstructured":"Hu, Y. et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 116, 2732\u20132741, https:\/\/doi.org\/10.1182\/blood-2009-11-256354 (2010).","journal-title":"Blood"},{"key":"15165_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2015.12.016","volume":"372","author":"HY Cha","year":"2016","unstructured":"Cha, H. Y. et al. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL. Cancer Lett 372, 65\u201374, https:\/\/doi.org\/10.1016\/j.canlet.2015.12.016 (2016).","journal-title":"Cancer Lett"},{"key":"15165_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.fct.2014.08.009","volume":"73","author":"J Jin","year":"2014","unstructured":"Jin, J. et al. Role of Nrf2 activation and NF-kappaB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol 73, 95\u2013104, https:\/\/doi.org\/10.1016\/j.fct.2014.08.009 (2014).","journal-title":"Food Chem Toxicol"},{"key":"15165_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.exer.2014.01.021","volume":"121","author":"P Palsamy","year":"2014","unstructured":"Palsamy, P., Bidasee, K. R. & Shinohara, T. Valproic acid suppresses Nrf2\/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells. Exp Eye Res 121, 26\u201334, https:\/\/doi.org\/10.1016\/j.exer.2014.01.021 (2014).","journal-title":"Exp Eye Res"},{"key":"15165_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbrc.2011.02.035","volume":"406","author":"N Mercado","year":"2011","unstructured":"Mercado, N. et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun 406, 292\u2013298, https:\/\/doi.org\/10.1016\/j.bbrc.2011.02.035 (2011).","journal-title":"Biochem Biophys Res Commun"},{"key":"15165_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.freeradbiomed.2015.07.155","volume":"89","author":"A Leone","year":"2015","unstructured":"Leone, A. et al. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radic Biol Med 89, 287\u2013299, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.07.155 (2015).","journal-title":"Free Radic Biol Med"},{"key":"15165_CR49","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149, 1226\u20131239 e1224, https:\/\/doi.org\/10.1053\/j.gastro.2015.05.061 (2015).","journal-title":"Gastroenterology"},{"key":"15165_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrgastro.2014.6","volume":"11","author":"T Shibata","year":"2014","unstructured":"Shibata, T. & Aburatani, H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 11, 340\u2013349, https:\/\/doi.org\/10.1038\/nrgastro.2014.6 (2014).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"15165_CR51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3892\/ijo.2015.3301","volume":"48","author":"Q Zhao","year":"2016","unstructured":"Zhao, Q. et al. Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells. Int J Oncol 48, 765\u2013773, https:\/\/doi.org\/10.3892\/ijo.2015.3301 (2016).","journal-title":"Int J Oncol"},{"key":"15165_CR52","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1089\/ars.2010.3219","volume":"13","author":"A Singh","year":"2010","unstructured":"Singh, A., Bodas, M., Wakabayashi, N., Bunz, F. & Biswal, S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 13, 1627\u20131637, https:\/\/doi.org\/10.1089\/ars.2010.3219 (2010).","journal-title":"Antioxid Redox Signal"},{"key":"15165_CR53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1158\/1535-7163.MCT-09-0589","volume":"9","author":"P Zhang","year":"2010","unstructured":"Zhang, P. et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9, 336\u2013346, https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0589 (2010).","journal-title":"Mol Cancer Ther"},{"key":"15165_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbagen.2013.10.006","volume":"1840","author":"S Jayakumar","year":"2014","unstructured":"Jayakumar, S., Kunwar, A., Sandur, S. K., Pandey, B. N. & Chaubey, R. C. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta 1840, 485\u2013494, https:\/\/doi.org\/10.1016\/j.bbagen.2013.10.006 (2014).","journal-title":"Biochim Biophys Acta"},{"key":"15165_CR55","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1158\/0008-5472.CAN-13-1616","volume":"73","author":"ME Abazeed","year":"2013","unstructured":"Abazeed, M. E. et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 73, 6289\u20136298, https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1616 (2013).","journal-title":"Cancer Res"},{"key":"15165_CR56","first-page":"1368","volume":"5","author":"C Sun","year":"2015","unstructured":"Sun, C. et al. Disturbance of redox status enhances radiosensitivity of hepatocellular carcinoma. Am J Cancer Res 5, 1368\u20131381 (2015).","journal-title":"Am J Cancer Res"},{"key":"15165_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-013-1260-x","volume":"116","author":"ZX Cong","year":"2014","unstructured":"Cong, Z. X. et al. Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol 116, 41\u201348, https:\/\/doi.org\/10.1007\/s11060-013-1260-x (2014).","journal-title":"J Neurooncol"},{"key":"15165_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","volume":"7","author":"Y Jeong","year":"2017","unstructured":"Jeong, Y. et al. Role of KEAP1\/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov 7, 86\u2013101, https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0127 (2017).","journal-title":"Cancer Discov"},{"key":"15165_CR59","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ejps.2013.05.009","volume":"49","author":"W Ben-Cherif","year":"2013","unstructured":"Ben-Cherif, W. et al. Circadian variation of Valproic acid pharmacokinetics in mice. Eur J Pharm Sci 49, 468\u2013473, https:\/\/doi.org\/10.1016\/j.ejps.2013.05.009 (2013).","journal-title":"Eur J Pharm Sci"},{"key":"15165_CR60","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gut.25.6.673","volume":"25","author":"PR Powell-Jackson","year":"1984","unstructured":"Powell-Jackson, P. R., Tredger, J. M. & Williams, R. Hepatotoxicity to sodium valproate: a review. Gut 25, 673\u2013681 (1984).","journal-title":"Gut"},{"key":"15165_CR61","doi-asserted-by":"publisher","unstructured":"Saha, S. K. et al. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells. Int J Mol Sci 18, https:\/\/doi.org\/10.3390\/ijms18051048 (2017).","DOI":"10.3390\/ijms18051048"},{"key":"15165_CR62","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1118\/1.2836953","volume":"35","author":"S Yonai","year":"2008","unstructured":"Yonai, S. et al. Evaluation of beam wobbling methods for heavy-ion radiotherapy. Med Phys 35, 927\u2013938, https:\/\/doi.org\/10.1118\/1.2836953 (2008).","journal-title":"Med Phys"},{"key":"15165_CR63","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24, 148\u2013154 (1989).","journal-title":"Cancer Chemother Pharmacol"},{"key":"15165_CR64","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6889","author":"SW Shin","year":"2017","unstructured":"Shin, S. W. et al. Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP. Antioxid Redox Signal. https:\/\/doi.org\/10.1089\/ars.2016.6889 (2017).","journal-title":"Antioxid Redox Signal"}],"updated-by":[{"DOI":"10.1038\/s41598-018-25326-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15165-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15165-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:13:00Z","timestamp":1671783180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15165-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15165"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15165-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]},"assertion":[{"value":"26 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14986"}}